^
Association details:
| Biomarker: | PD-L1 underexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | vibecotamab (XmAb14045) (CD3 agonist, CD123 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
Published date:
12/06/2020
Excerpt:
112 patients with relapsed or refractory AML had received vibecotamab....Biomarker analyses suggest that low baseline leukemic burden and low PD-1 expression on CD4+ and CD8+ T cells are independent predictors of response...The overall response rate (ORR) was 15% (n=8/54)...
